A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Phase 2 Active not recruiting 58 enrolled Onconic Therapeutics Inc.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor

Timeline

Start: 2022-08-31
Primary completion: 2024-11
Completion: 2025-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nesuparib	Small molecule	150 mg	—

A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Summary

Timeline

Drugs

Indications